Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interventions for Tobacco Dependent Adolescents
NCT00158171Phase 2Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Apr 2002
- Primary completion
- May 2004
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bupropion and nicotine patch in Tobacco Use Disorder (TUD) (4 arms), sponsored by National Institute on Drug Abuse. Primary endpoint: Reduction in tobacco toxicant exposure at 17 weeks. Started Apr 2002; status: completed.
02
Drugs
bupropionnicotine patch
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT00158171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00158171.